Skylar is an associate editorial director for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.
She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on LinkedIn.
Although crowdfunding can be a financial lifeline for young adult patients with serious medical conditions, the nuances regarding the need for and the long-term impact of crowdfunding exposes a facet of the US health care system that must be addressed.
Gillian Woollett, MA, Dphil, vice president and head of regulatory strategy and policy at Samsung Bioepis, gives insight into what international markets the United States could look to as examples of good biosimilar adoption.
Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives insight into how his practice will handle the influx of at least 7 adalimumab biosimilars referencing Humira that are expected to enter the market in 2023.
Michael Ciarametaro, MBA, vice president of research at the National Pharmaceutical Council, highlights steps clinics can take to mitigate issues related to data collection regarding cell and gene therapies.
Researchers found that implementing an incremental schedule for hemodialysis in patients with residual kidney disease produced similar clinical outcomes and significant savings for health systems compared with hemodialysis administered on a more traditional schedule.
Despite technological advancements, there are still many factors that can cause specimens for comprehensive genomic profiling (CGP) testing to become compromised, potentially leading to inaccurate prognostic results, according to a recent webinar.
Flow–minimal residual disease (MRD) assessment in patients with multiple myeloma (MM) was found to be a good tool for early detection of MRD and could aid providers in treatment decision-making.
A literature review outlined the number of fertility complications that men and women with chronic kidney disease (CKD) face as well as the list of potential factors that can impact fertility and sexual functions in this population.
A trastuzumab biosimilar was found to have similar safety and efficacy with the reference product (Herceptin) in patients with advanced gastric cancer, a population previously excluded from bioequivalence studies for trastuzumab biosimilars.
Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, provides her take on why practices will have to continue to stock multiple biosimilars for the same reference product.
Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, explains how payers can play an essential role in improving biosimilar adoption.
Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, gives her take on what payers should keep in mind when dealing with chimeric antigen receptor (CAR) T-cell therapies.
Pipeline forecasting can provide payers better insight into which expensive specialty drugs coming down the pipeline they should be keeping their eyes on, according to Katie Lockhart, MA, manager at Magellan Health.
Chelsee Jensen, PharmD, pharmaceutical formulary manager at Mayo Clinic, explains how the process of implementing biosimilars may differ depending on practice size.
Soumya Vishwanath, PharmD, senior manager of formulary strategy at Magellan Rx Management, highlighted the therapeutic gaps that need to be addressed to ensure that patients with behavioral health disorders are well cared for.
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed some of the regulatory and legal hurdles that generic and biosimilar companies have to face on the road to market launch.
Michael Ciarametaro, MBA, vice president of research at the National Pharmaceutical Council, discusses the balance between lowering drug prices and encouraging innovation in new drug classes for serious diseases.
A literature review pointed out the limited current research that has been conducted on how to manage pruritus in patients with chronic kidney disease (CKD) treated with hemodialysis, suggesting that more data is needed to improve symptom burden in these patients.
Melissa Andel, principal at CommonHealth Solutions, previewed her session on policy making and pricing reform at the upcoming Academy of Managed Care Pharmacy's annual meeting.
Investigators confirmed an association between fatty liver disease related to metabolic dysfunction (MAFLD) and chronic kidney disease (CKD), and stressed a greater focus on treating MAFLD is needed to help manage risks.
A new frailty-based outcome prediction model for multiple myeloma (MM) was found to be an easy-to-use tool in clinical practice and produced valid results based on a large real world cohort of patients with a new MM diagnosis, according to a recent study.
During the recent Association of Community Cancer Centers’ 2022 Annual Meeting & Cancer Center Business Summit, panelists suggested that the laser focus on rebates by pharmacy benefit managers (PBMs) may be hindering uptake of biosimilars, thereby keeping some off of formulary lists.
Risk stratification is a difficult process for multiple myeloma (MM), and authors concluded that their multi-tiered model may provide a greater risk assessment benefit than standard stratification systems.
Genome sequencing of tumors from children and adolescents with recurrent or refractory cancer led to over 100 patients receiving targeted therapies.
Finerenone (Kerendia) was found to reduce risk of heart failure and improve other cardiovascular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) regardless of heart failure history.
As the United States awaits market introduction for adalimumab biosimilars in 2023, 2022 is going to be the year of expanding access to biosimilars, according to Julie M. Reed, the new executive director of the Biosimilars Forum.
Researchers found that low levels of vitamin D and the prevalence of peripheral neuropathy were common in patients with multiple myeloma, suggesting that addressing the former could help prevent the latter.
Decorin, a highly conserved, class 1 small leucine-rich repeat proteoglycan expressed in the extracellular matrix, may have a protective effect in a subset of patients with multiple myeloma, investigators concluded.
Investigators concluded that early palliative care may be needed for more patients with multiple myeloma (MM) as pain can manifest in different ways and severity levels depending on disease state, suggesting that a more individualized approach is critical for pain management.
Releuko, a filgrastim biosimilar developed by Kashiv Biosciences and Amneal Pharmaceuticals, becomes the third filgrastim biosimilar to be approved by the FDA.
